Loading
Seres Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Nutritional Health LTP Fund General Partner LLC, was filed 07 Jul 2022.
Seres Therapeutics, Inc.: what insiders have been doing
Seres Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 5 insiders have disclosed 30 filings since 22 October 2025.
Only sales appear on the open market, 12 sales in all totalling €44k, filed by 5 insiders. At €19k, the sale published on 18 November 2025 by Henn Matthew R. is the largest of the period.
The median gap between a trade and its publication by SEC (Form 4) is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 30 filings, this issuer sits above that mark. Our records for Seres Therapeutics, Inc. go back to 2016, with 3 purchases and 161 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of 5.7 m USD.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
334
Thresholds
n/a
Buy Volume
€36M
3 ops. · all time
Sell Volume
€52M
161 ops. · all time
Who traded when
BuySaleEric D. Shaff7 sales
Matthew R. Henn7 sales
Thomas DesRosier7 sales
Teresa L. Young6 sales
Lisa von Moltke2 sales
Kelly Brady1 sale
Since the insiders bought
- +18.8%Entry US$81.00 · Close at T+365 US$96.20
- +81.7%Entry US$53.50 · Close at T+365 US$97.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,425 of 26,240 companies
38.0
score / 100
Value70
Quality6
FCF yld3.7%
Earn yld25%
EV/EBITDA10.8x
ROE-67%
Gross mgn·
Net mgn·
Debt/EBITDA8.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.31
Analyst consensus
2 analysts1.00/5
US$12.00Target US$17.00(+636%)US$22.00
Income statement
RevenueUS$789k
Gross profit-US$5.8M-729% margin
EBITDAUS$9.8M1246% margin
Net incomeUS$5.7M721.9% margin
Valuation
PER (forward)-0.5x
P/Book0.7x
Beta0.31
Balance sheet & cash
Market capUS$23.2M
Total debtUS$83M
Free Cash FlowUS$865k
Debt / Equity164%
Profitability & ownership
ROE-66.6%
ROA-39.8%
% insiders11.5%
% institutions22.8%
Last declaration on 18 August 2026
Declarations334 total
722 sharesCommon StockSEC:0001193125-26-355722:0
263 shares@ US$4.550.0033% mcap0.5% of flowCommon StockSEC:0001193125-26-355722:1
181 sharesCommon StockSEC:0001193125-26-355734:0
64 shares@ US$4.550.0008% mcap100.0% of flowCommon StockSEC:0001193125-26-355734:1
245 sharesCommon StockSEC:0001193125-26-355712:0
82 shares@ US$4.550.0010% mcap0.2% of flowCommon StockSEC:0001193125-26-355712:1
238 sharesCommon StockSEC:0001193125-26-355718:0
81 shares@ US$4.550.0010% mcap100.0% of flowCommon StockSEC:0001193125-26-355718:1
89 shares@ US$8.473.0% of flowCommon StockSEC:0001193125-26-057153:1
259 shares@ US$8.470.2% of flowCommon StockSEC:0001193125-26-057156:1
78 shares@ US$8.470.2% of flowCommon StockSEC:0001193125-26-057154:1
75 shares@ US$8.471.0% of flowCommon StockSEC:0001193125-26-057157:1
231 sharesCommon StockSEC:0001193125-26-057157:0
723 sharesCommon StockSEC:0001193125-26-057156:0
244 sharesCommon StockSEC:0001193125-26-057154:0
239 sharesCommon StockSEC:0001193125-26-057153:0
112 sharesCommon StockSEC:0001193125-25-286240:1
331 sharesCommon StockSEC:0001193125-25-286235:1
140 sharesCommon StockSEC:0001193125-25-286226:1
98 sharesCommon StockSEC:0001193125-25-286226:2
132 sharesCommon StockSEC:0001193125-25-286236:1
98 sharesCommon StockSEC:0001193125-25-286236:2
217 shares@ US$17.300.3% of flowCommon StockSEC:0001193125-25-286235:2
1,257 shares@ US$17.3088.2% of flowCommon StockSEC:0001193125-25-286226:3
1,042 shares@ US$17.3028.4% of flowCommon StockSEC:0001193125-25-286236:3
25 of 334 declarations
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (NASDAQ: MCRB) is a U.S.-listed biotechnology company traded on the NASDAQ market in the United States. Headquartered in Cambridge, Massachusetts, Seres focuses on a highly specialized corner of healthcare: live biotherapeutics designed to modulate the human microbiome and address serious diseases with significant unmet medical need. The company was founded in 2010 and built its reputation on a scientific platform centered on rationally selected bacterial consortia. Its team also helped pioneer the development and FDA approval of VOWST™, the first oral live biotherapeutic, which was sold to Nestlé Health Science in September 2024.
Following that strategic divestiture, Seres has narrowed its focus to research and development, with SER-155 as its lead program. SER-155 is being developed to prevent bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), a clinically important setting with high infection risk and substantial unmet need. The company has disclosed that SER-155 has received Breakthrough Therapy designation for reducing bloodstream infections in this population, as well as Fast Track designation for reducing infection risk and graft-versus-host disease risk. In 2025, Seres reported encouraging clinical and translational biomarker data from its Phase 1b study, outlined preparations for a Phase 2 protocol, and said it had received constructive FDA feedback, while also noting that additional capital would be required to advance the program.
Read moreShow less
From a competitive standpoint, Seres operates in a scientifically demanding niche where differentiation depends on platform credibility, clinical execution, and regulatory progress. The company presents itself as a leader in microbiome therapeutics, but it remains small relative to large-cap pharmaceutical groups. Its geographic footprint is concentrated in Cambridge, Massachusetts, with core research, development, and operating activities based in the United States.
Recent notable developments include the VOWST™ sale, the strategic refocus on SER-155, active partnership and financing discussions, and governance changes in July 2025, when CEO Eric Shaff departed and interim co-CEOs were appointed. For investors, Seres Therapeutics remains a high-risk, high-optional biotech story: scientifically differentiated, but still highly dependent on clinical success, funding access, and regulatory execution.
